Concert Pharmaceuticals is a biopharmaceutical company focused on developing small molecule drugs for a variety of medical conditions, including central nervous system disorders, genetic diseases, and inflammatory disease. The company's clinical-stage product candidates include AVP-786, CTP-499, and CTP-354, which are currently in various stages of clinical trials. AVP-786 is being studied as a treatment for neurologic and psychiatric disorders, while CTP-499 is being tested for chronic kidney disease in type 2 diabetes patients. CTP-354 is in its early stages of clinical trials for spasticity associated with spinal cord injury and multiple sclerosis.